Invivyd, Inc. SEC filings IVVD
Invivyd, Inc. has 448 filings in SEC EDGAR's recent list, going back to Nov 12, 2020. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 23, 2025 | — |
| CORRESP | Letter to the SEC | Dec 19, 2025 | — |
| EFFECT | Filing | Apr 19, 2024 | — |
| CORRESP | Letter to the SEC | Apr 18, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2024 | — |
| D | Filing | Nov 29, 2022 | — |
| EFFECT | Filing | Oct 5, 2022 | — |
| CORRESP | Letter to the SEC | Oct 3, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2022 | — |
| DEFA14C | Filing | Jun 21, 2022 | — |
| DFAN14A | Filing | Jun 6, 2022 | — |
| DEFC14C | Filing | Jun 2, 2022 | — |
| CORRESP | Letter to the SEC | May 31, 2022 | — |
| PRER14C | Filing | May 31, 2022 | — |
| UPLOAD | Letter from the SEC | May 27, 2022 | — |
| DEFA14C | Filing | May 19, 2022 | — |
| PREC14C | Filing | May 19, 2022 | — |
| DEFC14A | Filing | Apr 29, 2022 | — |
| PRRN14A | Filing | Apr 27, 2022 | — |
| PREC14A | Filing | Apr 26, 2022 | — |
| PRRN14A | Filing | Apr 25, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 18, 2022 | — |
| PREC14A | Filing | Apr 11, 2022 | — |
| SEC STAFF LETTER | Filing | Aug 13, 2021 | — |
| EFFECT | Filing | Aug 5, 2021 | — |
| CERT | Filing | Aug 5, 2021 | — |
| CORRESP | Letter to the SEC | Aug 3, 2021 | — |
| CORRESP | Letter to the SEC | Aug 3, 2021 | — |
| CORRESP | Letter to the SEC | Aug 3, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 3, 2021 | — |
| 8-A12B | Filing | Aug 3, 2021 | — |
| CORRESP | Letter to the SEC | Aug 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2021 | — |
| SEC STAFF LETTER | Filing | Jul 16, 2021 | — |
| CORRESP | Letter to the SEC | Jul 16, 2021 | — |
| DRS/A | Filing | Jul 13, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2021 | — |
| DRSLTR | Filing | Jun 28, 2021 | — |
| DRS/A | Filing | Jun 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2021 | — |
| DRS | Filing | May 21, 2021 | — |
| D | Filing | Apr 30, 2021 | — |
| D | Filing | Nov 12, 2020 | — |
| D | Filing | Nov 12, 2020 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IVVD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1832038
- Former names
- Adagio Therapeutics, Inc. (until Sep 12, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.